Related Experiment Video
Updated: Aug 7, 2026

Contrast Enhanced Ultrasound Imaging for Assessment of Spinal Cord Blood Flow in Experimental Spinal Cord Injury
Published on: May 7, 2015
Major bleeding complications in patients treated with direct oral anticoagulants: One-year observational study in a
1Service de pharmacie, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France.
Insights
Direct oral anticoagulants (DOACs) offer benefits but can cause severe bleeding. Managing these bleeding complications is challenging due to the lack of specific antidotes, necessitating careful risk-benefit assessment.
Area of Science:
- Pharmacology
- Clinical Medicine
- Hemorrhagic Complications
Background:
- Direct oral anticoagulants (DOACs) are increasingly prescribed for venous thromboembolism and stroke prevention in atrial fibrillation.
- DOACs offer advantages over vitamin K antagonists (VKAs) but pose bleeding risks.
- Managing DOAC-associated bleeding is complex due to the absence of specific reversal agents.
Purpose of the Study:
- To report and discuss major hemorrhagic complications associated with DOAC therapy.
- To highlight the challenges in managing DOAC-induced bleeding.
- To emphasize the importance of risk-benefit assessment before initiating DOACs.
Main Methods:
- Retrospective case series analysis.
- Pharmacological surveillance data from Saint-Louis University Hospital (Paris, France).
- Review of five cases of major hemorrhagic complications over one year.
Main Results:
- Five cases of major hemorrhagic complications under DOAC therapy were identified.
- Treatment of these severe bleeding events presented significant clinical challenges.
- The study underscores the complexity of managing DOAC-related hemorrhages.
Conclusions:
- DOACs, despite their benefits, are associated with potentially severe bleeding.
- Effective management strategies for DOAC-induced bleeding complications are crucial.
- A thorough risk-benefit evaluation is essential for safe DOAC prescription.
Abstract:
Direct oral anticoagulants (DAOC) are indicated for the treatment of venous thromboembolism and the prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation. Given their advantages and friendly use for patient, the prescription of long term DOAC therapy has rapidly increased both as first line treatment while initiating anticoagulation and as a substitute to vitamins K antagonist (VKA) in poorly controlled patients. However, DOAC therapy can also be associated with significant bleeding complications, and in the absence of specific antidote at disposal, treatment of serious hemorrhagic complications under DOAC remains complex. We report and discuss herein five cases of major hemorrhagic complications under DOAC, which were reported to the pharmacological surveillance department over one year at Saint-Louis University Hospital (Paris, France). We further discuss the need for careful assessment of the risk/benefit ratio at time of starting DOAC therapy in daily clinical practice.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care